Cell Membrane-Coated Nanoparticles for Cancer Immunotherapy

Purpose: Cancer immunotherapy is limited by tumor heterogeneity, immune cell disability, immunosuppressive tumor microenvironment (TME), and systemic immune toxicity. Cell membrane-coated nanoparticles (CMCNs) offer a biomimetic delivery strategy that inherits source-cell functions—immune evasion, tumor targeting, and biological compatibility—to precisely deliver immunotherapeutic drugs and enhance anti-cancer immunity. ---

Hypothesis: The review’s central thesis is: if synthetic nanoparticle cores are coated with natural cell membranes, then the resulting CMCNs can combine the delivery advantages of nanoparticles with the biological functions of source cells—enabling immune evasion, prolonged circulation, tumor targeting, TME regulation, and enhanced cancer immunotherapy with reduced systemic toxicity. ---

Aims: - Summarize recent research on biomimetic CMCNs for cancer immunotherapy. - Outline common cancer immunotherapies and their clinical limitations. - Explore the unique functions and molecular mechanisms of various cell membrane-coated nanoparticles. - Analyze challenges facing CMCN clinical translation. ---

Delivery system: CMCN architecture: - Cell membrane-derived vesicles (CMVs) from: erythrocytes, leukocytes (macrophages, dendritic cells, NK cells), cancer cells, platelets, bacteria, mesenchymal stem cells (MSCs), and hybrid membranes. - Nanoparticle cores: biodegradable polyesters (PLGA, PLA, PCL), silica, metal nanoparticles (gold, Fe₃O₄), nanogels, metal–organic frameworks (MOFs). - Preparation methods: extrusion, ultrasonic method, microfluidic electroporation. Payloads / cargos: - Immunotherapeutic drugs, immune checkpoint blockade (ICB) inhibitors, cytokines (IL-2), adjuvants (R848, R837, CpG), tumor antigens, photosensitizers, chemotherapeutic drugs (DOX, oxaliplatin), siRNA (e.g., PD-L1 siRNA). Targeting / functional molecules: - Erythrocyte membrane: CD47, CR1, CD59, C8bp — “self” markers, immune escape, long circulation. - Macrophage membrane: CCR2, VCAM-1, ICAM-1, CD45, CD11a, integrins — inflammation/tumor targeting. - DC membrane: peptide/MHC complexes, ICAM-3, CD40, CD44, CCR7 — antigen presentation, lymph node homing. - NK cell membrane: NKG2D, NKp44, NKp46, NKp30, DNAM-1 — tumor targeting. - Cancer cell membrane: CD47, E-cadherin, EpCAM, Thomsen–Friedenreich antigens, galectin-3 — homotypic targeting, immune escape. - Platelet membrane: P-selectin, CD47, CD55, CD59 — tumor and circulating tumor cell targeting. - Bacterial membrane: PAMPs (LPS, lipoprotein, DNA, RNA) — adjuvant effects. - MSC membrane: CXCR1/2/4/5, CCR9, TGF-β, E-/P-selectins — tumor tropism. ---

Approach: Narrative review of preclinical and clinical literature. Model systems discussed include: - In vitro: dendritic cell maturation, NK cell activation, T cell activation, antigen presentation, macrophage polarization. - In vivo: mouse tumor models including B16-F10 melanoma, 4T1/TNBC breast cancer, colorectal cancer, ovarian cancer, and others. - Disease context: cancer vaccines, adoptive cellular immunotherapy, cytokine immunotherapy, immune checkpoint blockade, TME regulation, combination therapy with chemotherapy/phototherapy/radiotherapy. ---

Key methods: Techniques and endpoints highlighted across cited studies: - Flow cytometry for DC maturation, T cell subsets, M1/M2 macrophage polarization, NK activation. - ELISA for cytokine secretion (IFN-γ, TNF-α, IL-2, etc.). - Confocal microscopy and electron microscopy for membrane coating and cellular uptake. - In vivo tumor growth inhibition, survival analysis, metastasis assessment. - Lymph node targeting and antigen presentation assays. - Competitive binding assays for PD-1/PD-L1 blockade. - Immunohistochemistry and immunofluorescence for immune cell infiltration. ---

Key results: - Cancer vaccine response rates: clinical patient response to cancer vaccines remains relatively low at 11–50%; ICB inhibitors show ~80% effective rate in lymphoma but only 10–30% in solid tumors. - Sipuleucel-T (Provenge) extends overall survival by 4.1 months in metastatic castration-resistant prostate cancer. - APMC vaccine (B16F10 cancer cell membrane-coated CpG/aluminum phosphate nanoparticles): increased DC maturation, enhanced cellular/humoral immunity, improved tumor prevention/treatment and longer mouse survival vs. membrane vesicles alone. - PIR@M nanoparticles (macrophage membrane-coated PLGA-Fe₃O₄-R837): increased tumor M1 macrophage ratio from 11.27% to 29.44%; similar effect in spleen. - AM@DLMSN@CuS/R848 (cancer cell membrane-coated mesoporous silica with CuS/R848 and anti-PD-1 peptide): competitive binding rate >70%; anti-PD-1-FITC positive rate dropped from 34.5% to 9.79% in splenic lymphocytes. - R@HTR (erythrocyte membrane-coated Hb-TiO₂-RRx-001): increased M1 transformation, mature DCs, CTL infiltration; reduced Tregs and MDSCs; reversed immunosuppressive TME and prolonged survival. - CMNP (cancer cell membrane-coated Fe₃O₄@SiO₂): activated naive NK cells, upregulated activation receptors, stimulated granzyme/perforin secretion. ---

Interpretation: The authors claim that CMCNs inherit abundant source-cell functions—“self” markers, immune system cross-talk, biological targeting, and homing—giving them better biocompatibility, weak immunogenicity, immune escaping, prolonged circulation, and tumor targeting. CMCNs can deliver immunotherapeutic drugs, regulate the immunosuppressive TME, induce immunogenic cell death, promote antigen release/presentation, and activate NK/T cells. They conclude that CMCNs have natural advantages and enormous potential for cancer immunotherapy, although clinical translation still faces challenges. ---

Limitations: - Large-scale production: extrusion method is low-throughput and difficult to scale industrially. - Membrane extraction/purification: differential centrifugation may leave cytoplasmic residues, causing immunogenicity; membrane fragments may be lost. - Membrane protein stability: functional proteins can be inactivated during extraction/fusion. - Nanoparticle core safety: FDA-approved, low-toxicity materials (e.g., PLGA) are preferred for clinical translation. - Cancer heterogeneity: personalized treatment may be needed. - Lack of clear regulations, policies, and safety evaluation guidelines for CMCN clinical translation. - Complex design may hinder clinical translation compared with simpler biomimetic carriers.